Literature DB >> 24306927

Etiology of familial breast cancer with undetected BRCA1 and BRCA2 mutations: clinical implications.

Eugenia Yiannakopoulou1.   

Abstract

BACKGROUND: Familial breast cancer accounts for 20-30 % of all breast cancer cases. Mutations in the BRCA1 and BRCA2 genes account for the majority of high risk families with both early onset breast cancer and ovarian cancer. Most of the families with less than six breast cancer cases and no ovarian cancer do not carry BRCA1 or BRCA2 mutations that can be detected using routine sequencing protocols. Here, we aimed to review the etiology of familial breast cancer in cases without BRCA1 and BRCA2 mutations.
RESULTS: After excluding BRCA1 and BRCA2 mutations, factors proposed to contribute to familial breast cancer include: chance clustering of apparently sporadic cases, shared lifestyle, monogenic inheritance, i.e., dominant gene mutations associated with a high risk (TP53, PTEN, STK11), dominant gene mutations associated with a relatively low risk (ATM, BRIP1, RLB2), recessive gene mutations associated with horizontal inheritance patterns (sister-sister), and polygenic inheritance where susceptibility to familial breast cancer is thought to be conferred by a large number of low risk alleles.
CONCLUSIONS: Current evidence suggests that in the majority of cases with BRCA1 and BRCA2 negative familial breast cancer the etiology is due to interactions of intermediate or low risk alleles with environmental and lifestyle factors. Thus, a careful selection of patients submitted to genetic testing is needed. Clearly, further research is required to fully elucidate the etiology of non-BRCA familial breast cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24306927     DOI: 10.1007/s13402-013-0158-0

Source DB:  PubMed          Journal:  Cell Oncol (Dordr)        ISSN: 2211-3428            Impact factor:   6.730


  82 in total

Review 1.  Inheritance of epigenetic aberrations (constitutional epimutations) in cancer susceptibility.

Authors:  Megan P Hitchins
Journal:  Adv Genet       Date:  2010       Impact factor: 1.944

2.  ATM: ready, set, go.

Authors:  Yosef Shiloh
Journal:  Cell Cycle       Date:  2003 Mar-Apr       Impact factor: 4.534

3.  Increased risk of breast cancer associated with CHEK2*1100delC.

Authors:  Maren Weischer; Stig Egil Bojesen; Anne Tybjaerg-Hansen; Christen Kirk Axelsson; Børge Grønne Nordestgaard
Journal:  J Clin Oncol       Date:  2006-07-31       Impact factor: 44.544

4.  Prognostic value of acquired uniparental disomy (aUPD) in primary breast cancer.

Authors:  Musaffe Tuna; Marcel Smid; John W M Martens; John A Foekens
Journal:  Breast Cancer Res Treat       Date:  2011-05-21       Impact factor: 4.872

5.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

Authors:  D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

6.  BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history.

Authors:  K E Malone; J R Daling; J D Thompson; C A O'Brien; L V Francisco; E A Ostrander
Journal:  JAMA       Date:  1998-03-25       Impact factor: 56.272

7.  E-cadherin gene mutations provide clues to diffuse type gastric carcinomas.

Authors:  K F Becker; M J Atkinson; U Reich; I Becker; H Nekarda; J R Siewert; H Höfler
Journal:  Cancer Res       Date:  1994-07-15       Impact factor: 12.701

Review 8.  ATM and the Mre11 complex combine to recognize and signal DNA double-strand breaks.

Authors:  M F Lavin
Journal:  Oncogene       Date:  2007-12-10       Impact factor: 9.867

9.  PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene.

Authors:  Nazneen Rahman; Sheila Seal; Deborah Thompson; Patrick Kelly; Anthony Renwick; Anna Elliott; Sarah Reid; Katarina Spanova; Rita Barfoot; Tasnim Chagtai; Hiran Jayatilake; Lesley McGuffog; Sandra Hanks; D Gareth Evans; Diana Eccles; Douglas F Easton; Michael R Stratton
Journal:  Nat Genet       Date:  2006-12-31       Impact factor: 38.330

10.  Constitutive promoter methylation of BRCA1 and RAD51C in patients with familial ovarian cancer and early-onset sporadic breast cancer.

Authors:  Tamara Hansmann; Galyna Pliushch; Monika Leubner; Patricia Kroll; Daniela Endt; Andrea Gehrig; Sabine Preisler-Adams; Peter Wieacker; Thomas Haaf
Journal:  Hum Mol Genet       Date:  2012-07-27       Impact factor: 6.150

View more
  7 in total

1.  The cancer genome: from structure to function.

Authors:  Ad Geurts van Kessel
Journal:  Cell Oncol (Dordr)       Date:  2014-06       Impact factor: 6.730

2.  Decreased CDK10 expression correlates with lymph node metastasis and predicts poor outcome in breast cancer patients - a short report.

Authors:  Yanjie You; Haijun Li; Xin Qin; Yinpo Zhang; Wengang Song; Yonggang Ran; Fenglan Gao
Journal:  Cell Oncol (Dordr)       Date:  2015-09-21       Impact factor: 6.730

3.  A novel loss-of-function heterozygous BRCA2 c.8946_8947delAG mutation found in a Chinese woman with family history of breast cancer.

Authors:  Jing Ma; Jichun Yang; Wenjing Jian; Xianming Wang; Deyong Xiao; Wenjun Xia; Likuan Xiong; Duan Ma
Journal:  J Cancer Res Clin Oncol       Date:  2017-01-05       Impact factor: 4.553

4.  Prevalence of Germline Mutations in Genes Engaged in DNA Damage Repair by Homologous Recombination in Patients with Triple-Negative and Hereditary Non-Triple-Negative Breast Cancers.

Authors:  Pawel Domagala; Anna Jakubowska; Katarzyna Jaworska-Bieniek; Katarzyna Kaczmarek; Katarzyna Durda; Agnieszka Kurlapska; Cezary Cybulski; Jan Lubinski
Journal:  PLoS One       Date:  2015-06-17       Impact factor: 3.240

5.  Identification of miR-10b, miR-26a, miR-146a and miR-153 as potential triple-negative breast cancer biomarkers.

Authors:  Insaf Fkih M'hamed; Maud Privat; Flora Ponelle; Frédérique Penault-Llorca; Abderraouf Kenani; Yves-Jean Bignon
Journal:  Cell Oncol (Dordr)       Date:  2015-09-21       Impact factor: 6.730

6.  Genomic rearrangement screening of the BRCA1 from seventy Iranian high-risk breast cancer families.

Authors:  Maryam Sedghi; Elham Esfandiari; Esmat Fazel-Najafabadi; Mansoor Salehi; Abbas Salavaty; Shirin Fattahpour; Leila Dehghani; Nayerossadat Nouri; Fariborz Mokarian
Journal:  J Res Med Sci       Date:  2016-11-02       Impact factor: 1.852

7.  BRCA1 c.68_69delAG (exon2), c.181T>G (exon5), c.798_799delTT and 943ins10 (exon11) mutations in Burkina Faso.

Authors:  Abdou Azaque Zoure; Meriem Slaoui; Hierrhum Aboubacar Bambara; Alexis Yobi Sawadogo; Tegwendé Rebeca Compaoré; Nabonswindé Lamoussa Marie Ouédraogo; Mohammed El Mzibri; Mohammed Attaleb; Si Simon Traoré; Jacques Simpore; Youssef Bakri
Journal:  J Public Health Afr       Date:  2018-07-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.